Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

被引：5
|
作者：
Elmeliegy, Mohamed [1 ]
Lon, Hoi Kei [1 ]
Wang, Diane [1 ]
Ma, Wei An [1 ]
King, Lindsay [2 ]
Viqueira, Andrea [3 ]
Czibere, Akos [2 ]
机构：
[1] Pfizer, San Diego, CA USA
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer SLU, Madrid 28108, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
    Bahlis, Nizar J.
    Raje, Noopur S.
    Costello, Caitlin
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Levy, Moshe Y.
    Tomasson, Michael H.
    Dube, Harman
    Liu, Feng
    Liao, Kai Hsin
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Chu, Michael P.
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    van de Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [43] Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review
    Shah, Zunairah
    Batool, Syeda Sabeeka
    Fazeel, Hafiz Muhammad
    Malik, Mustafa Nadeem
    Sadiq, Maryam
    Hassan, Syeda Fatima
    Syed, Tariq Iqtidar Sadiq
    Abdullah, Syed Maaz
    Javed, Nisma
    Ashraf, Aqsa
    Farooqui, Arafat Ali Ali
    Yousaf, Muhammad Abdullah
    Ahmad, Muhaddis Ejaz
    Ghani, Marium
    Akbar, Arshia
    Anwer, Faiz
    BLOOD, 2019, 134
  • [44] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
  • [45] Targeting B-cell maturation antigen in multiple myeloma
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    IMMUNOTHERAPY, 2015, 7 (11) : 1187 - 1199
  • [46] A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Noopur, Raje
    Xavier, Leleu
    Alexander, Lesokhin M.
    Mohamed, Mohty
    Ajay, Nooka
    Eric, Leip
    Umberto, Conte
    Andrea, Vlqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S17 - S18
  • [47] B-Cell Maturation Antigen (BCMA) as a Biomarker for Assessing Multiple Myeloma Progression and Relapse
    Joshi, Hemant
    Wolters, Emily
    Firpo-Betancourt, Adolfo
    Mendu, Damodara Rao
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1424 - S1425
  • [48] A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Plesner, Torben
    Harrison, Simon J.
    Quach, Hang
    Lee, Cindy H.
    Bryant, Adam
    Vangsted, Annette Juul
    Estell, Jane
    Delforge, Michel
    Offner, Fritz
    Twomey, Patrick
    Choeurng, Voleak
    Li, Junyi
    Hendricks, Robert
    Sumiyoshi, Teiko
    Miller, Karen
    Choi, Eunpi
    Schjesvold, Fredrik H.
    BLOOD, 2021, 138
  • [49] Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
    Mammadzadeh, Aytaj
    Peng, Fulei
    Atrash, Shebli
    Hashmi, Hamza
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    BLOOD, 2022, 140 : 4277 - 4278
  • [50] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
    Cortes-Selva, Diana
    Casneuf, Tineke
    Vishwamitra, Deeksha
    Stein, Sarah
    Perova, Tatiana
    Skerget, Sheri
    Ramos, Elena
    van Steenbergen, Laure
    De Maeyer, Dries
    Boominathan, Rengasamy
    Lau, Onsay
    Davis, Cuc
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa M.
    Kobos, Rachel
    Goldberg, Jenna D.
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad
    Bahlis, Nizar Jacques
    Van de Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2022, 140
12345